Manuscript no. HAEMATOL/2012/062059 entitled “Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research”


Information about the contributions of each person named as having participated in the study

1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:
   • Armand Keating, MD; Princess Margaret Hospital, University of Toronto, Ontario, Canada; armand.keating@uhn.ca
   • Daniel J. Weisdorf, MD; University of Minnesota Medical Center, Minneapolis, MN; weisd001@umn.edu

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_1author.html): “Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 ... Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the conception of the study:
   • Armand Keating, MD; Princess Margaret Hospital, University of Toronto, Ontario, Canada

3) Design & Methods. The following authors were responsible for specific investigations:
   • Armand Keating, MD and Daniel Weisdorf, MD were responsible for the study design
   • Gisela DaSilva, PhD was responsible for the statistical methodology

4) Results. The following authors were responsible for specific portions of the results, including figures and tables (please indicate the person responsible for each figure and each table):
   • Waleska S. Pérez, MPH prepared the dataset and perform the univariate analysis.
   • Ms. Pérez was responsible for table 1, 2 and 4; figures 1a, 1b, 2a and 2b
   • Gisela DaSilva, PhD performed the multivariate analyses
   • Dr. DaSilva was responsible for table 3

5) Writing the manuscript. The following authors were responsible for writing the manuscript:
   • Armand Keating, MD and Daniel Weisdorf, MD were responsible for the writing and supervision of the writing of the manuscript.
   • Vikas Gupta, MD, Corey S. Cutler, MD, MPH, Karen K. Ballen, MD, Mitchell S. Cairo, MD, Bruce M. Camitta, MD, Richard E. Champlin, MD, James L. Gajewski, MD, Robert Peter Gale, MD, PhD, DSc, Hillard M. Lazarus, MD, Michael Lill, MD, David I. Marks, MD, PhD, Gustavo A. Milone, MD, Gary J. Schiller, MD, Jorge G. Sierra, MD, Gerald Socie, MD, PhD,
Chadi Nabhan, MD, Jeffrey Szer, MD, Martin S. Tallman, MD and Roy S. Weiner, MD were responsible for reviewing the interpretation of the analysis, suggesting modifications to the writing, reviewing the manuscript and approval of the manuscript.

6) Contributors Listed in Acknowledgments: (Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair who provided only general support. Corresponding authors must declare whether they had assistance with the study design, data collection, data analysis, or manuscript preparation. If such assistance was available, the authors must disclose the identity of the individuals who provided this assistance and the entity that supported it. Financial and material support should also be acknowledged.)

This study was supported through the Center for International Blood and Marrow Transplant Research (CIBMTR).

CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI; a contract HHSF234200637015C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research; and grants from Allos, Inc.; Amgen, Inc.; Angioblast; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children’s Leukemia Research Association; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; Kiadis Pharma; The Leukemia & Lymphoma Society; The Medical College of Wisconsin; Millennium Pharmaceuticals, Inc.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Optum Healthcare Solutions, Inc.; Otsuka America Pharmaceutical, Inc.; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; Swedish Orphan Biovitrum; THERAKOS, Inc.; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, or any other agency of the U.S. Government.